dry%20eye%20syndrome
DRY EYE SYNDROME

Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.

Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.

Dry%20eye%20syndrome Management

Follow Up

  • The patient is advised to follow up, in order to assess their response to therapy, if there is a need to alter or adjust the treatment & to monitor structural ocular damage, as well as to provide reassurance
  • Frequency & extent of follow-up will depend on the severity of the disease, therapeutic approach & response to therapy

Counselling

  • Clinicians should provide their patients w/ proper instructions for their therapeutic regimens, as well as caution them about LASIK, as this may worsen their dry eye condition
    • May refer their patients to an appropriate specialist, if there are other causes or underlying conditions that would contribute to having dry eye 
  • Patients should be educated about the chronic nature of the disease & its process
    • Their compliance, understanding of the disease, risks for structural changes should periodically be reassessed
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.